DK0737186T3 - Fremgangsmåde til fremstilling af leukotrienantagonister - Google Patents

Fremgangsmåde til fremstilling af leukotrienantagonister

Info

Publication number
DK0737186T3
DK0737186T3 DK95906106T DK95906106T DK0737186T3 DK 0737186 T3 DK0737186 T3 DK 0737186T3 DK 95906106 T DK95906106 T DK 95906106T DK 95906106 T DK95906106 T DK 95906106T DK 0737186 T3 DK0737186 T3 DK 0737186T3
Authority
DK
Denmark
Prior art keywords
preparation
compound
formula
leukotriene antagonists
het
Prior art date
Application number
DK95906106T
Other languages
English (en)
Inventor
Mahadevan Bhupathy
James M Mcnamara
Daniel R Sidler
Ralph P Volante
James J Bergan
Hsien-Hsin Tung
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26870681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0737186(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK0737186T3 publication Critical patent/DK0737186T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/53—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
DK95906106T 1993-12-28 1994-12-22 Fremgangsmåde til fremstilling af leukotrienantagonister DK0737186T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17493193A 1993-12-28 1993-12-28
US35042894A 1994-12-09 1994-12-09
PCT/US1994/014858 WO1995018107A1 (en) 1993-12-28 1994-12-22 Process for the preparation of leukotriene antagonists

Publications (1)

Publication Number Publication Date
DK0737186T3 true DK0737186T3 (da) 1999-02-08

Family

ID=26870681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95906106T DK0737186T3 (da) 1993-12-28 1994-12-22 Fremgangsmåde til fremstilling af leukotrienantagonister

Country Status (28)

Country Link
US (2) US5614632A (da)
EP (1) EP0737186B1 (da)
JP (1) JP3640962B2 (da)
KR (1) KR100319336B1 (da)
CN (3) CN1046712C (da)
AT (1) ATE169906T1 (da)
AU (1) AU686303B2 (da)
BG (1) BG62850B1 (da)
BR (1) BR9408452A (da)
CA (1) CA2179407C (da)
CY (1) CY2104B1 (da)
CZ (1) CZ286079B6 (da)
DE (1) DE69412644T2 (da)
DK (1) DK0737186T3 (da)
ES (1) ES2122534T3 (da)
FI (1) FI113045B (da)
GE (1) GEP20012387B (da)
HR (1) HRP941022B1 (da)
HU (1) HU226394B1 (da)
LV (1) LV12313B (da)
NZ (1) NZ278263A (da)
PL (1) PL178671B1 (da)
RO (1) RO119018B1 (da)
RU (2) RU2140909C1 (da)
TW (2) TW448160B (da)
UA (1) UA44724C2 (da)
WO (1) WO1995018107A1 (da)
YU (1) YU49412B (da)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
WO2001047889A1 (en) * 1999-12-28 2001-07-05 Ube Industries, Ltd. Tricyclic compounds
JP4308667B2 (ja) * 2002-02-06 2009-08-05 デルマー ケミカルズ インコーポレーテッド １−（メルカプトメチル）−シクロプロパン酢酸の調製方法
AU2003209043A1 (en) * 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
JP2006523699A (ja) * 2003-04-15 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド モンテルカストナトリウムの多形形態
AU2004234235A1 (en) 2003-04-25 2004-11-11 Nippon Chemiphar Co., Ltd. Salt of (2s,3s)-3-[[(1s)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid
CA2528228C (en) * 2003-06-06 2011-09-20 Morepen Laboratories Limited A method for the preparation of montelukast acid and sodium salt thereof in amorphous form
AU2004283832B2 (en) 2003-10-10 2011-04-07 Synthon B.V. Solid-state montelukast
EP1760077A1 (en) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
CA2554572A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
WO2005075427A2 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
BRPI0506610A (pt) 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
EP1646612B1 (en) * 2004-04-21 2009-07-01 Teva Pharmaceutical Industries Ltd Processes for preparing montelukast sodium
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
WO2006008750A2 (en) * 2004-07-19 2006-01-26 Matrix Laboratories Ltd Methyl 2-[(3s)-[3-[(2e)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates
ATE500225T1 (de) * 2004-07-19 2011-03-15 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen davon
WO2006021974A1 (en) * 2004-08-23 2006-03-02 Morepen Laboratories Limited A process for synthesizing diol (viii)-an intermediate of montelukast sodium
PL205637B1 (pl) * 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
US20080146809A1 (en) * 2004-11-19 2008-06-19 Matrix Laboratories Ltd Process for the Preparation of Novel Amorphous Montelukast Sodium
WO2006058545A1 (en) * 2004-11-30 2006-06-08 Medichem, S.A. New process for the preparation of a leukotriene antagonist
ITMI20050247A1 (it) * 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
CN101213177A (zh) 2005-07-05 2008-07-02 特瓦制药工业有限公司 孟鲁司特的纯化
WO2007012075A2 (en) * 2005-07-20 2007-01-25 Dr. Reddy's Laboratories Ltd. Preparation of montelukast
EP1783117A1 (en) * 2005-11-04 2007-05-09 Esteve Quimica, S.A. Process for the preparation of a leukotriene antagonist and intermediates thereof
EP1948612A2 (en) * 2005-11-16 2008-07-30 Teva Pharmaceutical Industries Ltd Drying methods of montelukast sodium by azeotropic removal of the solvent
AR057908A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast e intermediarios del mismo
US8178680B2 (en) * 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
EP1968942A4 (en) * 2005-12-23 2010-06-02 Glade Organics Private Ltd IMPROVED METHOD FOR THE PRODUCTION OF MONTELUCASTIC SODIUM
PT1976522E (pt) 2005-12-30 2013-09-09 Krka Tovarna Zdravil D D Novo Mesto Composição farmacêutica contendo montelucaste
US7572930B2 (en) * 2006-02-02 2009-08-11 Chemagis Ltd. Process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof
CA2635841A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
WO2007096875A2 (en) * 2006-02-21 2007-08-30 Chemagis Ltd. Novel polymorphs of montelukast ammonium salts and processes for preparation therefor
WO2007096889A2 (en) * 2006-02-27 2007-08-30 Chemagis Ltd. Process for preparing montelukast and salts thereof
CN101432267A (zh) 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
EP2004608B1 (en) * 2006-04-12 2011-09-14 Glade Organics Private Limited An improved process for the manufacture of montelukast sodium
WO2008001213A1 (en) * 2006-06-26 2008-01-03 Aurobindo Pharma Limited An improved process for the preparation of leukotriene receptor antagonist (montelukast sodium)
GB0614485D0 (en) * 2006-07-21 2006-09-27 Pliva Istrazivanje I Razvoj D Process
US20110092708A1 (en) * 2006-08-04 2011-04-21 Seeta Ramanjaneyulu Gorantla Process for the preparation of montelukast and its salts thereof
EP1886998A1 (en) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Purification process of montelukast and its amine salts
NZ575552A (en) * 2006-09-15 2012-02-24 Cipla Ltd Process for the preparation of montelukast, and intermediates therefor
GB0618703D0 (en) * 2006-09-22 2006-11-01 Almac Sciences Ltd Synthesis of leikotriene compounds
US7700776B2 (en) 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
EP2094665A4 (en) * 2006-11-06 2010-11-24 Reddys Lab Ltd Dr PREPARATION OF MONTELUKAST AND ITS SALTS
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
KR100774088B1 (ko) * 2006-12-14 2007-11-06 한미약품 주식회사 몬테루카스트의 제조방법 및 이에 사용되는 중간체
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
EP1958936A1 (en) * 2007-02-14 2008-08-20 Inke, S.A. Process for obtaining montelukast
WO2008126075A1 (en) * 2007-04-12 2008-10-23 Chemagis Ltd. Process for preparing montelukast and salts thereof using optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl-2-propanol
WO2008135966A1 (en) * 2007-05-02 2008-11-13 Chemagis Ltd. Process for the purification of optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxy-propyl)phenyl-2-propanol
PL205444B1 (pl) * 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
CZ302518B6 (cs) * 2007-07-09 2011-06-29 Zentiva, A. S. Zpusob izolace a cištení montelukastu
EP2014633A1 (en) * 2007-07-13 2009-01-14 Lonza Ag Process for the production of tertiary alcohols
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
WO2009027990A1 (en) * 2007-08-29 2009-03-05 Morepen Laboratories Limited Salts of montelukast and process therefor
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
AU2008316284A1 (en) * 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
EP2053043A1 (en) 2007-10-26 2009-04-29 Inke, S.A. Crystalline salt of montelukast
DE102007061630B4 (de) 2007-12-20 2013-07-04 Formosa Laboratories, Inc. Neue Verbindungen und Herstellung von Montelukast-Natrium
EP2231613B1 (en) * 2008-01-07 2011-10-12 Torrent Pharmaceuticals Ltd. Montelukast benzhydryl piperazine salts and process for preparation thereof
CN101323589B (zh) * 2008-03-06 2010-10-06 台耀化学股份有限公司 化合物及孟鲁司特钠的制备方法
CN101817818B (zh) * 2008-03-06 2011-10-26 台耀化学股份有限公司 一种用于制备孟鲁司特钠的化合物
WO2009117381A2 (en) * 2008-03-17 2009-09-24 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
CA2723398C (en) * 2008-05-05 2017-07-04 Abbott Gmbh & Co. Kg Method for evaluating the solubility of a crystalline substance in a polymer
WO2009144742A2 (en) 2008-05-26 2009-12-03 Aptuit Laurus Pvt Limited An improved process for preparing montelukast and salts thereof
KR101123292B1 (ko) * 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2010064109A2 (en) 2008-12-02 2010-06-10 Mayuka Labs Private Limited An improved process for the preparation of montelukast sodium and its intermediates
WO2010148209A2 (en) * 2009-06-19 2010-12-23 Dr. Reddy's Laboratories Ltd. Preparation of montelukast
WO2011004298A1 (en) 2009-07-09 2011-01-13 Alembic Limited Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2287154A1 (en) * 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
CN101638381B (zh) 2009-09-02 2012-08-29 鲁南制药集团股份有限公司 孟鲁司特钠中间体的合成方法
WO2011033470A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Crystalline form of montelukast sodium
EP2486015A1 (en) * 2009-10-09 2012-08-15 DSM IP Assets B.V. Sythesis of optically active intermediate for the preparation of montelukast
WO2011076237A1 (en) 2009-12-23 2011-06-30 Pharmathen S.A. Improved process for the preparation of montelukast and salts thereof
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (en) 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Camphorsulfonic salt of a key Montelukast intermediate
CN102633683B (zh) * 2012-04-06 2014-05-21 盐城市晶华化工有限公司 一种1-羟甲基环丙基乙腈合成方法
EP2850064B1 (en) * 2012-05-18 2018-11-07 Laurus Labs Limited Process for preparation of montelukast sodium
CN103539714A (zh) * 2012-07-16 2014-01-29 上海朴颐化学科技有限公司 1-巯甲基环丙基乙酸及其中间体的制备方法
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
WO2014081616A1 (en) * 2012-11-21 2014-05-30 Merck Sharp & Dohme Corp. Preparation of precursors for leukotriene antagonists
WO2014118796A1 (en) 2013-01-31 2014-08-07 Melody Healthcare Pvt. Ltd. An in-situ process for the preparation of highly pure montelukast sodium
CN103570618A (zh) * 2013-09-30 2014-02-12 浙江车头制药股份有限公司 一种孟鲁司特钠盐的制备方法
EP3096760A1 (en) 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN104119270A (zh) * 2014-08-12 2014-10-29 牡丹江恒远药业有限公司 一种孟鲁司特钠的制备方法
CN105085391B (zh) * 2015-06-10 2017-08-22 广东默泰同创医药科技有限公司 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用
CN105541786B (zh) * 2016-01-06 2017-08-08 鲁南贝特制药有限公司 一种孟鲁司特钠侧链中间体及其制备方法
CN109503476A (zh) * 2018-12-26 2019-03-22 哈尔滨珍宝制药有限公司 一种孟鲁司特钠的合成工艺
CN111170939A (zh) * 2019-12-20 2020-05-19 牡丹江恒远药业股份有限公司 一种高纯度孟鲁司特钠及其中间体的制备方法
CN117024340A (zh) * 2023-07-27 2023-11-10 迪嘉药业集团股份有限公司 一种孟鲁司特钠的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188235B (en) * 1982-12-11 1986-03-28 Alkaloida Vegyeszeti Gyar,Hu Process for producing fluoro-methyl-quinoline derivatives
CA1288436C (en) * 1983-07-22 1991-09-03 David Paul Hesson Phenylquinolinecarboxylic acids and derivatives as antitumor agents
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
CA2053209C (en) * 1990-10-12 1998-12-08 Michel L. Belley Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5428033A (en) * 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5358946A (en) * 1992-05-29 1994-10-25 The Du Pont Merck Pharmaceutical Company Heterocycle-substituted amides, carbamates and ureas as agents for the treatment of atherosclerosis
US5270234A (en) * 1992-10-30 1993-12-14 International Business Machines Corporation Deep submicron transistor fabrication method
CA2111372C (en) * 1992-12-22 2007-01-16 Robert N. Young Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists
US5371096A (en) * 1993-08-27 1994-12-06 Ciba-Geigy Corporation (3-pyridyl)tetrafuran-2-yl substituted carboxylic acids

Also Published As

Publication number Publication date
JP3640962B2 (ja) 2005-04-20
CN101081834A (zh) 2007-12-05
JPH09507235A (ja) 1997-07-22
YU49412B (sh) 2006-01-16
CZ187896A3 (en) 1996-12-11
CN101081834B (zh) 2011-08-24
DE69412644T2 (de) 1999-02-11
HRP941022A2 (en) 1997-06-30
LV12313B (en) 1999-11-20
CN1139429A (zh) 1997-01-01
FI962641L (fi) 1996-06-26
US5614632A (en) 1997-03-25
BG62850B1 (bg) 2000-09-29
HK1009269A1 (en) 1999-05-28
CA2179407C (en) 2009-03-17
CN1219535A (zh) 1999-06-16
WO1995018107A1 (en) 1995-07-06
HRP941022B1 (en) 1999-12-31
NZ278263A (en) 1998-04-27
TW448160B (en) 2001-08-01
CY2104B1 (en) 2002-04-05
RU2140909C1 (ru) 1999-11-10
YU77594A (sh) 1997-09-30
EP0737186A1 (en) 1996-10-16
PL315155A1 (en) 1996-10-14
EP0737186B1 (en) 1998-08-19
FI962641A0 (fi) 1996-06-26
AU686303B2 (en) 1998-02-05
ATE169906T1 (de) 1998-09-15
LV12313A (lv) 1999-07-20
HU9601775D0 (en) 1996-09-30
UA44724C2 (uk) 2002-03-15
CN1326837C (zh) 2007-07-18
ES2122534T3 (es) 1998-12-16
CA2179407A1 (en) 1995-07-06
AU1444895A (en) 1995-07-17
FI113045B (fi) 2004-02-27
PL178671B1 (pl) 2000-05-31
HU226394B1 (en) 2008-11-28
CZ286079B6 (cs) 2000-01-12
BR9408452A (pt) 1997-08-05
GEP20012387B (en) 2001-03-25
US6320052B1 (en) 2001-11-20
BG100638A (bg) 1997-03-31
RO119018B1 (ro) 2004-02-27
KR100319336B1 (ko) 2002-04-22
DE69412644D1 (de) 1998-09-24
RU2225398C2 (ru) 2004-03-10
CN1046712C (zh) 1999-11-24
HUT76279A (en) 1997-07-28
TW416948B (en) 2001-01-01

Similar Documents

Publication Publication Date Title
FI962641A0 (fi) Menetelmä leukotrieeniantagonistien valmistamiseksi
YU164791A (sh) Nezasićene hidroksialkilhinolin kiseline
NO931656D0 (no) Fremgangsmaate for fremstilling av aryl-piperazinyl-heterocykliske forbindelser
NO178969C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte kinazolinoner
ES509242A0 (es) "procedimiento para preparar nuevos compuestos de cefem".
DK160989C (da) 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-(alkylsubstitueret 1-piperazinyl)-3-quinolincarboxylsyrer og farmaceutisk anvendelse syreadditions-, alkalimetal- og jordalkalimetalsalte og hydrater deraf, disse forbindelser til behandling af bakterielle sygdomme samt antibakterielle midler indeholdende disse forbindelser
NO902301D0 (no) Fremgangsmaate for fremstilling av diarylstyrylkinolin-disyrer.
IL88303A (en) Derivatives of 6-fluoro-7-û4-( (5-methyl-2-oxo-1,3- dioxolen-4-yl)methyl) piperazin-1-ylù-4 (1h)-oxo-1,3-thiazeto(3,2-a) quinoline-3-carboxylic acid
ES8700666A1 (es) Procedimiento para la preparacion de derivados de 2-(piridi-lalquilenosulfinil)benzimidazoles n-substituidos como agen- tes antisecretorios gastricos
AU8293387A (en) Quinoline compound
ES2005746A6 (es) Un procedimiento para la preparacion de un haluro de piridinio.
PT83104B (en) Novel guanidinomethylbenzoic acid derivatives
ES8506652A1 (es) Un metodo de preparar dihidrobenzopirrolbenzodiazepinas
ES8504718A1 (es) Un metodo para preparar derivados de 4-hidroxi-2-quinolona.
KR970006302A (ko) 4-아미노-3-아실나프티리딘 유도체
EP0331078A3 (en) Process for the preparation of optically active 4-oxo-1-benzopyran-2-carboxylic acid derivatives and intermediates thereof
PT80791A (fr) Procede de preparation de nouvelles phenyl-naphtiridines utiles notamment comme medicaments anti-ulceres
JPS55104295A (en) Pyrimidin-4-yl(thio)phosphoric acid ester, its preparation, and insecticide, miticide, and nematocide containing the compound as effective component
ATE239699T1 (de) Hydroxyphenylsulfanylbenzoesäure- und - arylessigsäure-derivate
ES2061406A1 (es) Nuevos derivados de la 2-(quinolina) con actividad farmacologica.
JPS57154167A (en) Pharmaceutical composition having diuretic, hypotensive and antihydropic activity
YU49499B (sh) Supstituisani hinolinski herbicidni intermedijari i postupak za njihovo dobijanje
ES2006917A6 (es) Un procedimiento para la preparacion del acido 1-etil-6-fluor-4-oxo-7-morfolin-1,4-dihidro-3-quinolincarboxilico.
JPS6416746A (en) Anisole derivative and production thereof
BR9909959A (pt) Método para a produção de cristais de elevado ponto de fusão de derivado de ácido fenoxipropiÈnico